Neuroendocrine Carcinoma of the Rectum as a Cause of Acute Obstructive Abdomen. Case Report and Literature Review
DOI:
https://doi.org/10.56294/saludcyt2024975Keywords:
Surgery, Oncology, Surgical OncologyAbstract
Rectal neuroendocrine carcinoma, though rare, is experiencing an increase in its incidence, representing approximately 1 % of all colorectal cancers. A growth in its incidence has been observed in recent decades, albeit with varying figures geographically. Research studies such as those by Dasari et al. (2017) and Scherübl et al. (2014) have indicated a significant rise in the incidence of these tumors, especially in the United States and Europe. Although it can manifest in different age groups, it is more common in middle-aged or older adults, without a clear gender predilection. Symptoms may include changes in bowel habits, rectal bleeding, abdominal pain, unexplained weight loss, and fatigue, varying according to the degree of tumor differentiation and the presence of metastasis. We present the case of a 65-year-old woman who presented with obstructive symptoms and was subsequently found to have neuroendocrine tumor post-surgery
References
1. Stoffel EM, Murphy CC. Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. Gastroenterology. enero de 2020;158(2):341-53.
2. Burnett-Hartman AN, Lee JK, Demb J, Gupta S. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset colorectal cancer. Gastroenterology. marzo de 2021;160(4):1041-9.
3. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. diciembre de 2019;16(12):713-32.
4. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przegla̜d Gastroenterol. 2019;14(2):89-103.
5. Irby K, Anderson WF, Henson DE, Devesa SS. Emerging and widening colorectal carcinoma disparities between Blacks and Whites in the United States (1975-2002). Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. abril de 2006;15(4):792-7.
6. Park HC, Shin A, Kim BW, Jung KW, Won YJ, Oh JH, et al. Data on the characteristics and the survival of korean patients with colorectal cancer from the Korea central cancer registry. Ann Coloproctology. agosto de 2013;29(4):144-9.
7. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 1 de febrero de 2010;116(3):544-73.
8. De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P, et al. Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep. septiembre de 2015;34(3):1087-96.
9. Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 8 de junio de 2011;305(22):2304-10.
10. Ricciardiello L, Ahnen DJ, Lynch PM. Chemoprevention of hereditary colon cancers: time for new strategies. Nat Rev Gastroenterol Hepatol. junio de 2016;13(6):352-61.
11. Calva D, Howe JR. Hamartomatous polyposis syndromes. Surg Clin North Am. agosto de 2008;88(4):779-817, vii.
12. Lutgens MWMD, van Oijen MGH, van der Heijden GJMG, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789-99.
13. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. junio de 2012;10(6):639-45.
14. Nottage K, McFarlane J, Krasin MJ, Li C, Srivastava D, Robison LL, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol Off J Am Soc Clin Oncol. 10 de julio de 2012;30(20):2552-8.
15. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. junio de 2018;19(6):758-67.
16. Luo W, Cao Y, Liao C, Gao F. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Dis Off J Assoc Coloproctology G B Irel. noviembre de 2012;14(11):1307-12.
17. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 1 de octubre de 2017;3(10):1335-42.
18. Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc. 16 de octubre de 2010;2(10):325-34.
19. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 1 de octubre de 2009;27(28):4656-63.
20. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 17 de julio de 2014;371(3):224-33.
Published
Issue
Section
License
Copyright (c) 2024 Marcos Lenin Zambrano Avellán, Rolando Alberto Castro Cardenas, Villacis Hidalgo Yerlyn Narcisa, Stefhany Tatiana Guerrero Saltos, María Lorena Armijos Pazmiño, María José Peña Pibaque, Flavio Hernan Ante Guanotuña, Josseline Sofía Solano Zambrano, Priscilla Martina Vera Gaibor, Israel Josue Neira Serrano, Rodrigo Hernández Ramírez, Reina Narváez Fabián Esteban, Pamela Elizabeth Vega Chanalata (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
